# DIEBOLD NIXDORF, Inc: financial statements, quarterly

DBD · NYSE · CIK 28823 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dbd.md) · [Financials](/companies/dbd/financials.md) · [Filings](/companies/dbd/filings.md) · [Insiders](/companies/dbd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dbd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-03-31) | Q2 FY2024 (2023-06-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [858](/filings/0000028823-24-000041.md) | [922](/filings/0000028823-24-000076.md) | [895](/filings/0000028823-25-000057.md) | [940](/filings/0000028823-25-000075.md) | [927](/filings/0000028823-25-000083.md) | [989 d](/filings/0000028823-26-000008.md) | [841](/filings/0000028823-26-000021.md) | [915](/filings/0000028823-26-000033.md) | [945](/filings/0000028823-25-000083.md) | [1,104 d](/filings/0000028823-26-000008.md) | [892](/filings/0000028823-26-000021.md) | [931](/filings/0000028823-26-000033.md) |
| Cost of revenue | $m | [649](/filings/0000028823-24-000041.md) | [697](/filings/0000028823-24-000076.md) | [687](/filings/0000028823-25-000057.md) | [697](/filings/0000028823-25-000075.md) | [691](/filings/0000028823-25-000083.md) | [757 d](/filings/0000028823-26-000008.md) | [639](/filings/0000028823-26-000021.md) | [681](/filings/0000028823-26-000033.md) | [700](/filings/0000028823-25-000083.md) | [824 d](/filings/0000028823-26-000008.md) | [679](/filings/0000028823-26-000021.md) | [691](/filings/0000028823-26-000033.md) |
| Gross profit | $m | [209](/filings/0000028823-24-000041.md) | [225](/filings/0000028823-24-000076.md) | [209](/filings/0000028823-25-000057.md) | [243](/filings/0000028823-25-000075.md) | [237](/filings/0000028823-25-000083.md) | [232 d](/filings/0000028823-26-000008.md) | [202](/filings/0000028823-26-000021.md) | [234](/filings/0000028823-26-000033.md) | [245](/filings/0000028823-25-000083.md) | [280 d](/filings/0000028823-26-000008.md) | [213](/filings/0000028823-26-000021.md) | [240](/filings/0000028823-26-000033.md) |
| Research and development | $m | [26.4](/filings/0000028823-24-000041.md) | [25.4](/filings/0000028823-24-000076.md) | [24.2](/filings/0000028823-25-000057.md) | [22.1](/filings/0000028823-25-000075.md) | [23.4](/filings/0000028823-25-000083.md) | [23.9 d](/filings/0000028823-26-000008.md) | [22.7](/filings/0000028823-26-000021.md) | [22.4](/filings/0000028823-26-000033.md) | [20.3](/filings/0000028823-25-000083.md) | [21.4 d](/filings/0000028823-26-000008.md) | [22.1](/filings/0000028823-26-000021.md) | [20.5](/filings/0000028823-26-000033.md) |
| Selling, general and administrative | $m | [184](/filings/0000028823-24-000041.md) | [201](/filings/0000028823-24-000076.md) | [162](/filings/0000028823-25-000057.md) | [152](/filings/0000028823-25-000075.md) | [165](/filings/0000028823-25-000083.md) | [165 d](/filings/0000028823-26-000008.md) | [152](/filings/0000028823-26-000021.md) | [154](/filings/0000028823-26-000033.md) | [151](/filings/0000028823-25-000083.md) | [176 d](/filings/0000028823-26-000008.md) | [157](/filings/0000028823-26-000021.md) | [162](/filings/0000028823-26-000033.md) |
| Operating income | $m | [(2.1)](/filings/0000028823-24-000041.md) | [(3.9)](/filings/0000028823-24-000076.md) | [23.8](/filings/0000028823-25-000057.md) | [70.7](/filings/0000028823-25-000075.md) | [46.4](/filings/0000028823-25-000083.md) | [41.2 d](/filings/0000028823-26-000008.md) | [29.6](/filings/0000028823-26-000021.md) | [56.2](/filings/0000028823-26-000033.md) | [73.8](/filings/0000028823-25-000083.md) | [82.4 d](/filings/0000028823-26-000008.md) | [32.7](/filings/0000028823-26-000021.md) | [57.4](/filings/0000028823-26-000033.md) |
| Interest expense | $m | [81.9](/filings/0000028823-24-000041.md) | [69.7](/filings/0000028823-23-000140.md) | [43.6](/filings/0000028823-24-000041.md) | [38.6](/filings/0000028823-25-000075.md) | [38.4](/filings/0000028823-25-000083.md) | [34.7 d](/filings/0000028823-26-000008.md) | [21.5](/filings/0000028823-26-000021.md) | [21.8](/filings/0000028823-26-000033.md) | [21.8](/filings/0000028823-25-000083.md) | [20.6 d](/filings/0000028823-26-000008.md) | [23.3](/filings/0000028823-26-000021.md) | [24.1](/filings/0000028823-26-000033.md) |
| Income tax | $m | [21.1](/filings/0000028823-24-000041.md) | [(24.8)](/filings/0000028823-24-000076.md) | [(3.1)](/filings/0000028823-25-000057.md) | [32.0](/filings/0000028823-25-000075.md) | [29.9](/filings/0000028823-25-000083.md) | [5.5 d](/filings/0000028823-26-000008.md) | [(2.2)](/filings/0000028823-26-000021.md) | [4.8](/filings/0000028823-26-000033.md) | [9.6](/filings/0000028823-25-000083.md) | [11.9 d](/filings/0000028823-26-000008.md) | [5.7](/filings/0000028823-26-000021.md) | [19.2](/filings/0000028823-26-000033.md) |
| Net income | $m | [(111)](/filings/0000028823-24-000041.md) | [(677)](/filings/0000028823-24-000076.md) | [(14.6)](/filings/0000028823-25-000057.md) | [14.9](/filings/0000028823-25-000075.md) | [(22.4)](/filings/0000028823-25-000083.md) | [5.6 d](/filings/0000028823-26-000008.md) | [(8.3)](/filings/0000028823-26-000021.md) | [12.2](/filings/0000028823-26-000033.md) | [41.1](/filings/0000028823-25-000083.md) | [49.6 d](/filings/0000028823-26-000008.md) | [5.0](/filings/0000028823-26-000021.md) | [15.5](/filings/0000028823-26-000033.md) |
| Diluted EPS | $ per share | [(1.40)](/filings/0000028823-24-000041.md) | [(8.46)](/filings/0000028823-24-000076.md) | [(0.39)](/filings/0000028823-25-000057.md) | [0.40](/filings/0000028823-25-000075.md) | [(0.60)](/filings/0000028823-25-000083.md) | not reported | [(0.22)](/filings/0000028823-26-000021.md) | [0.33](/filings/0000028823-26-000033.md) | [1.11](/filings/0000028823-25-000083.md) | not reported | [0.14](/filings/0000028823-26-000021.md) | [0.44](/filings/0000028823-26-000033.md) |
| Basic EPS | $ per share | [(1.40)](/filings/0000028823-24-000041.md) | [(8.46)](/filings/0000028823-24-000076.md) | [(0.39)](/filings/0000028823-25-000057.md) | [0.40](/filings/0000028823-25-000075.md) | [(0.60)](/filings/0000028823-25-000083.md) | not reported | [(0.22)](/filings/0000028823-26-000021.md) | [0.33](/filings/0000028823-26-000033.md) | [1.13](/filings/0000028823-25-000083.md) | not reported | [0.14](/filings/0000028823-26-000021.md) | [0.45](/filings/0000028823-26-000033.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-09-30) | FY2024 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [376](/filings/0000028823-24-000114.md) | [550](/filings/0000028823-25-000022.md) | [282](/filings/0000028823-24-000041.md) | [277](/filings/0000028823-24-000076.md) | [251](/filings/0000028823-24-000114.md) | [296](/filings/0000028823-26-000008.md) | [307](/filings/0000028823-25-000057.md) | [279](/filings/0000028823-25-000075.md) | [246](/filings/0000028823-25-000083.md) | [369](/filings/0000028823-26-000021.md) | [359](/filings/0000028823-26-000021.md) | not reported |
| Current assets | $m | [2,081](/filings/0000028823-23-000158.md) | [2,154](/filings/0000028823-25-000022.md) | [1,972](/filings/0000028823-24-000041.md) | [1,906](/filings/0000028823-24-000076.md) | [1,899](/filings/0000028823-24-000114.md) | [1,668](/filings/0000028823-26-000008.md) | [1,727](/filings/0000028823-25-000057.md) | [1,737](/filings/0000028823-25-000075.md) | [1,722](/filings/0000028823-25-000083.md) | [1,787](/filings/0000028823-26-000033.md) | [1,800](/filings/0000028823-26-000021.md) | [1,712](/filings/0000028823-26-000033.md) |
| Total assets | $m | [4,020](/filings/0000028823-23-000158.md) | [4,162](/filings/0000028823-25-000022.md) | [3,943](/filings/0000028823-24-000041.md) | [3,850](/filings/0000028823-24-000076.md) | [3,901](/filings/0000028823-24-000114.md) | [3,544](/filings/0000028823-26-000008.md) | [3,626](/filings/0000028823-25-000057.md) | [3,740](/filings/0000028823-25-000075.md) | [3,724](/filings/0000028823-25-000083.md) | [3,854](/filings/0000028823-26-000033.md) | [3,830](/filings/0000028823-26-000021.md) | [3,737](/filings/0000028823-26-000033.md) |
| Current liabilities | $m | [1,414](/filings/0000028823-23-000158.md) | [1,421](/filings/0000028823-25-000022.md) | [1,418](/filings/0000028823-24-000041.md) | [1,342](/filings/0000028823-24-000076.md) | [1,312](/filings/0000028823-24-000114.md) | [1,266](/filings/0000028823-26-000008.md) | [1,284](/filings/0000028823-25-000057.md) | [1,274](/filings/0000028823-25-000075.md) | [1,263](/filings/0000028823-25-000083.md) | [1,372](/filings/0000028823-26-000033.md) | [1,404](/filings/0000028823-26-000021.md) | [1,351](/filings/0000028823-26-000033.md) |
| Total liabilities | $m | [3,028](/filings/0000028823-23-000158.md) | [3,083](/filings/0000028823-25-000022.md) | [2,917](/filings/0000028823-24-000041.md) | [2,841](/filings/0000028823-24-000076.md) | [2,825](/filings/0000028823-24-000114.md) | [2,605](/filings/0000028823-26-000008.md) | [2,635](/filings/0000028823-25-000057.md) | [2,635](/filings/0000028823-25-000075.md) | [2,611](/filings/0000028823-25-000083.md) | [2,750](/filings/0000028823-26-000033.md) | [2,804](/filings/0000028823-26-000021.md) | [2,760](/filings/0000028823-26-000033.md) |
| Long-term debt | $m | [1,260](/filings/0000028823-23-000158.md) | [1,254](/filings/0000028823-25-000022.md) | [1,066](/filings/0000028823-24-000041.md) | [1,066](/filings/0000028823-24-000076.md) | [1,066](/filings/0000028823-24-000114.md) | [927](/filings/0000028823-26-000008.md) | [929](/filings/0000028823-25-000057.md) | [931](/filings/0000028823-25-000075.md) | [934](/filings/0000028823-25-000083.md) | [939](/filings/0000028823-26-000033.md) | [939](/filings/0000028823-26-000021.md) | [943](/filings/0000028823-26-000033.md) |
| Current portion of debt | $m | not reported | [0.3](/filings/0000028823-25-000022.md) | not reported | not reported | not reported | [0.2](/filings/0000028823-25-000057.md) | [0.3](/filings/0000028823-25-000057.md) | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [977](/filings/0000028823-23-000158.md) | [1,064](/filings/0000028823-25-000022.md) | [1,013](/filings/0000028823-24-000041.md) | [997](/filings/0000028823-24-000076.md) | [1,066](/filings/0000028823-24-000114.md) | [930](/filings/0000028823-26-000008.md) | [984](/filings/0000028823-25-000057.md) | [1,097](/filings/0000028823-25-000075.md) | [1,107](/filings/0000028823-25-000083.md) | [1,100](/filings/0000028823-26-000033.md) | [1,023](/filings/0000028823-26-000021.md) | [969](/filings/0000028823-26-000033.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-03-31) | Q2 FY2024 (2023-06-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(95.9)](/filings/0000028823-24-000041.md) | [(242) d](/filings/0000028823-24-000076.md) | [(23.5)](/filings/0000028823-25-000057.md) | [(8.0) d](/filings/0000028823-25-000075.md) | [(15.5) d](/filings/0000028823-25-000083.md) | [196 d](/filings/0000028823-26-000008.md) | [15.7](/filings/0000028823-26-000021.md) | [30.1 d](/filings/0000028823-26-000033.md) | [37.4 d](/filings/0000028823-25-000083.md) | [218 d](/filings/0000028823-26-000008.md) | [31.7](/filings/0000028823-26-000021.md) | [(13.6) d](/filings/0000028823-26-000033.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [1.8](/filings/0000028823-24-000041.md) | [1.1 d](/filings/0000028823-24-000076.md) | [0.0](/filings/0000028823-25-000057.md) | [0.0 d](/filings/0000028823-25-000075.md) | [0.0 d](/filings/0000028823-25-000083.md) | [0.0 d](/filings/0000028823-26-000008.md) | [9.6](/filings/0000028823-26-000021.md) | [30.1 d](/filings/0000028823-26-000033.md) | [39.9 d](/filings/0000028823-25-000083.md) | [51.1 d](/filings/0000028823-26-000008.md) | [60.4](/filings/0000028823-26-000021.md) | [60.6 d](/filings/0000028823-26-000033.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2019 (2019-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2024 (2023-03-31) | Q2 FY2024 (2023-06-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [76.7](/filings/0000028823-19-000165.md) | [79.1](/filings/0000028823-23-000158.md) | [79.3](/filings/0000028823-24-000041.md) | [80.0](/filings/0000028823-24-000076.md) | [37.6](/filings/0000028823-25-000057.md) | [37.7](/filings/0000028823-25-000075.md) | [37.6](/filings/0000028823-25-000083.md) | [37.6](/filings/0000028823-26-000021.md) | [37.5](/filings/0000028823-26-000033.md) | [37.0](/filings/0000028823-25-000083.md) | [35.7](/filings/0000028823-26-000021.md) | [35.3](/filings/0000028823-26-000033.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 33,946,588 at 2026-07-21, from the cover of the [10-Q filed 2026-07-29](/filings/0000028823-26-000033.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:18 ET. No prices; not investment advice.